These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 30558559

  • 1. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.
    BMC Nephrol; 2018 Dec 17; 19(1):361. PubMed ID: 30558559
    [Abstract] [Full Text] [Related]

  • 2. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhynov D.
    Transplantation; 2015 Dec 17; 99(12):2593-7. PubMed ID: 26371597
    [Abstract] [Full Text] [Related]

  • 3. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.
    Transplantation; 2013 Oct 15; 96(7):649-56. PubMed ID: 23842190
    [Abstract] [Full Text] [Related]

  • 4. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J.
    Am J Ther; 2013 Oct 15; 20(2):226-9. PubMed ID: 23466622
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H.
    Transplantation; 2013 Aug 27; 96(4):394-9. PubMed ID: 23736353
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab.
    Koutroutsos K, Charif R, Moran L, Moss J, Cook T, Roufosse C, Pusey C, Taube D, Loucaidou M.
    Clin Exp Nephrol; 2019 May 27; 23(5):700-709. PubMed ID: 30637591
    [Abstract] [Full Text] [Related]

  • 9. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ, Deegens JK, Wetzels JF.
    Pediatr Nephrol; 2013 Jul 27; 28(7):1041-8. PubMed ID: 23515666
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.
    Schenk H, Müller-Deile J, Schmitt R, Bräsen JH, Haller H, Schiffer M.
    J Clin Apher; 2017 Dec 27; 32(6):444-452. PubMed ID: 28370393
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pediatric focal segmental glomerulosclerosis: favorable transplantation outcome with plasma exchange.
    Fadel FI, Bazaraa HM, Abdel Mawla MA, Salah DM.
    Ital J Pediatr; 2021 Dec 14; 47(1):236. PubMed ID: 34906202
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W, Sunder-Plassmann G, Sengölge G, Handisurya A, Herkner H, Kornauth C, Bielesz B, Wagner L, Kikić Ž, Pajenda S, Reiter T, Schairer B, Schmidt A.
    Sci Rep; 2019 Sep 24; 9(1):13783. PubMed ID: 31551522
    [Abstract] [Full Text] [Related]

  • 15. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH.
    BMC Med; 2014 May 20; 12():81. PubMed ID: 24884842
    [Abstract] [Full Text] [Related]

  • 16. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A, Piecha G, Więcek A.
    Transplant Proc; 2016 Nov 20; 48(9):3092-3094. PubMed ID: 27932154
    [Abstract] [Full Text] [Related]

  • 17. ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation.
    Alhamad T, Manllo Dieck J, Younus U, Matar D, Alasfar S, Vujjini V, Wall D, Kanawati B, Reiser J, Brennan DC, Alachkar N.
    Transplantation; 2019 Jan 20; 103(1):202-209. PubMed ID: 29894413
    [Abstract] [Full Text] [Related]

  • 18. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.
    Alasfar S, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N.
    Transplantation; 2018 Mar 20; 102(3):e115-e120. PubMed ID: 29189487
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria.
    Abuzeineh M, Aala A, Alasfar S, Alachkar N.
    BMC Nephrol; 2020 Jul 02; 21(1):253. PubMed ID: 32615995
    [Abstract] [Full Text] [Related]

  • 20. Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis.
    Staeck O, Halleck F, Budde K, Khadzhynov D.
    Transplant Proc; 2017 Dec 02; 49(10):2256-2259. PubMed ID: 29198656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.